Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Receivables: 2012-2024

Historic Change in Receivables for Ani Pharmaceuticals (ANIP) over the last 13 years, with Dec 2024 value amounting to $21.1 million.

  • Ani Pharmaceuticals' Change in Receivables rose 419.57% to $27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.2 million, marking a year-over-year increase of 365.17%. This contributed to the annual value of $21.1 million for FY2024, which is 727.78% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Change in Receivables stood at $21.1 million for FY2024, which was up 727.78% from -$3.4 million recorded in FY2023.
  • Ani Pharmaceuticals' 5-year Change in Receivables high stood at $36.9 million for FY2022, and its period low was -$3.4 million during FY2023.
  • Moreover, its 3-year median value for Change in Receivables was $21.1 million (2024), whereas its average is $18.2 million.
  • In the last 5 years, Ani Pharmaceuticals' Change in Receivables slumped by 109.10% in 2023 and then spiked by 727.78% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Change in Receivables (Yearly) stood at $23.7 million in 2020, then plummeted by 76.56% to $5.5 million in 2021, then soared by 565.32% to $36.9 million in 2022, then crashed by 109.10% to -$3.4 million in 2023, then soared by 727.78% to $21.1 million in 2024.